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ABSTRACT
Biosimilars are the biological medicinal products that produce the therapeutic effects in the human body similar to that of inner biological molecule. 
Biopharmaceuticals consist of nucleic acids, amino acids, polysaccharides, or combination of all compounds. In India, the steps have been taken to 
manufacture biosimilars with the lowest cost and least side effects. Globally, India is one of the major developing countries in manufacturing and 
marketing of biosimilars. The application of biosimilar was rapidly growing in treating various disorders such as cancer, inflammatory disease, and 
cardiovascular diseases. For the approval of biosimilars, in vitro studies become the necessity for representing comparison to a standard biological 
in terms of quality for experimental studies indicating similar pharmacokinetics, efficacy, safety, and immunogenicity. Huminsulin was the first DNA-
recombinant protein accepted by the US Food and Drug Administration (FDA) in 1982. As currently there are no FDA-approved biosimilars for treating 
breast cancer, many biologic antibodies are under investigation.
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INTRODUCTION
A biosimilar may be a biological medicinal product that is nearly 
the same copy of an imaginative product which is made by a special 
company. Biosimilar is additionally referred to as inning biological or 
subsequent entry biological [1].
Generic medications which are made up of single compounds are 
totally different from biologically active compounds obtained by 
applying biotechnology to discover molecules from living systems 
such as bacteria, yeast, plant, virus, animal, or human cell lines that 
are biotechnologically modified to provide the drugs. Biosimilars are 
advanced bio-therapeutically produced drugs consisting of nucleic 
acids, amino acids, carbohydrates, or combination of these compounds.
Recently, biosimilars are manufactured from the human living system, 
especially cell lines as the post-translational modification that occurs in 
the non-human living systems. The safety and therapeutic effect of the 
final product should not be disturbed by any heterogeneous variations 
in its quality between different batches [2].
Biosimilars can be manufactured by studying pharmacokinetic and 
pharmacodynamic studies and compared to that of reference product 
which takes about 5 years. In pre-clinical studies, the variations in amino 
acid structure, immunogenicity, Absorption distribution metabolism 
excretion (ADME) studies, and biological responses will be detected by 
various investigative tools. This leads to the requirement for pre-clinical 
studies in developing biosimilars which were analyzed by various 
regulatory bodies [3]. Biosimilar monoclonal antibody, namely infliximab, 
was approved by “European Medical Agency” to treat inflammatory 
bowel disease [4,5]. In spite of the rigorous method made public by many 
bodies globally for the authorization of biosimilar, some physicians were 
not willing to use biosimilar, significantly in beneficial indication [5].
In the next upcoming years, subsequent entry biologics will be used 
to treat rheumatoid arthritis and most of the surveys have been 
reported stating that it would be appreciated if pharmacists have the 
rights to alternate the generic drugs with the biosimilars without 
clinician’s consent [6]. In oncology, biosimilars have been developed 
for the trastuzumab, rituximab, and bevacizumab. ABP 215, BCD-021, 
PF-06439535, and RPH-001 are the biosimilars for bevacizumab, 
whereas for the trastuzumab - BCD-022, CT-P6, FTMB/ABP 980, and 
PF-05280014 are the biosimilars [7].
GUIDANCE ON BIOSIMILAR DEVELOPMENT
For the development of biosimilars, the World Health Organization 
recommends to conduct categorization and similitude study for its 
properties, responses, impurities, and its stability additionally to pre-
clinical and clinical analysis and therapeutic indications [8-10]. Various 
applicable regulations and guidelines include Recombinant DNA Safety 
Guidelines (1990), Guidelines and Handbook for Institutional Biosafety 
Committees (2011), Guidelines on Similar Biologics: Regulatory 
Requirements for Marketing authorization in India (2012), Guidelines 
for Generating Preclinical and Clinical Data for rDNA Vaccines, 
Diagnostics, and Other Biologicals (1999), and CDSCO guidance for 
industry (2008). Recently, various researches toward the development 
of biologically similar products were carried out in the US, Europe, 
Israel, China, and Brazil [11,12].
vaccine, monoclonal antibodies, recombinant proteins, insulin, 
erythropoietin, streptokinase, and epidermal growth factor receptor 
were approved in India as Biosimilars [13-15]. Health Canada and 
European Medicines Agency (EMA) approve the products that show 
the resemblance in its biological responses with that of standard which 
compares the PKs, efficacy, safety, and immunogenicity [16-18]. The 
developing countries have taken steps to develop the biosimilars with 
low prices and side effects [9,19]. Several biosimilar products have 
previously been accepted and sold in Asian nation for diverse types of 
cancer [20,21].
PHARMACOECONOMIC IMPACT OF BIOSIMILARS
Globally, every year financial status of cancer that has been used for 
diagnosis and therapy was found to be approximately US$1.16 trillion 
in 2010 [22,23], and further, it was raised to US$2.5 trillion. In the 
Asian nation, people have to pay for their personal physical condition 
and patients are less possible to access individually to valuable cancer 
treatment [24,25].
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Pharmaceutical products are one of the major equipment to prevent, 
cure, diagnose/modify disease processes so as to reduce diseased 
condition, disabilities, and death. Upcoming information of various 
human diseases increased the invention of various targets or proteins 
toward the disease. The identified proteins create the idea for 
planning of discovering various pharmaceutical formulations to alter 
the pharmacological responses and clinical outcomes. Humulin (human 
insulin) was the first DNA-recombinant protein which was approved by 
the US Food and Drug Administration (FDA) in 1982 by Genentech and 
Eli Lilly [26,27]. Hence, there increased the development of a variety of 
biologics in treating several disorders such as cancer, inflammation, and 
cardiovascular-metabolic disorders [28,29].
COMPLICATION OF BIOSIMILARS IN STRUCTURE AND FUNCTIONS
Biologics are pharmaceutical preparations that are produced or extracted 
from biological sources with extremely complicated structures. Hence, 
biologics was different from chemically synthesized generic molecule 
which has conventional structures and functions. They are classified 
into organism antibodies, receptor modulators, or enzyme modulators. 
Biologics are manufactured from various systems and process such as 
heterogeneous mammalian cell lines, microorganisms, natural sources, 
recombinant DNA technology, and gene coding isolation [30]. To retain 
the triple or quadruple structures, the biosimilar products contain extra 
groups such as polypeptides, fatty acid, and amino acid sequences. It is 
necessary to include various additives to store it and also to influence 
the structure. These higher molecular weight preparations also 
need formulations including stabilizing and preservative agents for 
storage, which might have effect to increase their pharmacokinetic and 
pharmacodynamic properties.
IMMUNOLOGY
As these pharmaceutical products originate from a mammalian cell, 
immunogenicity remains a clear stage that it may provoke sensitivity or 
alter the responses with clinical effects. By focusing on these 
numerous issues, manufacturing of biosimilars is significantly 
difficult and takes longer when compared to generic molecules. 
It is easy to manufacture the generic drugs from batch to batch 
differences as it contains only carbon, oxygen, and nitrogen, which 
are easier to synthesize with low batch-to-batch variabilities [31]. 
Thus, immunogenicity against biological product or constituents of 
the preparation could result in decreased effectiveness or therapy 
negligence. Rarely, these elicited immunoglobulins could aim for the 
intracellular mediators leading to undesirable reactions like Diamond-
Blackfan anemia with epoetin [32].
BIOPHARMACEUTICALS IN BREAST CANCER
While there are currently no FDA-approved biosimilars of drugs that 
treat breast cancer, many biologic antibodies are under investigation. 
Trastuzumab, a monoclonal antibody that targets human epidermal 
growth factor receptor 2 (HER2), was shown to hinder the breast cancer 
cell proliferation that overexpresses HER2. In 2001, it was shown to 
improve the overall pharmacological response and its duration along 
with survival rate in combination with chemotherapy compared with 
chemotherapy alone. This led to the approval of trastuzumab in treating 
HER2-positive metastatic breast cancer in 2006. Since then, trastuzumab 
approval has expanded to cover additional settings, treatment regimens, 
and cancer types. In 2008, about more than 420,000 women with HER2-
positive breast cancer had received trastuzumab treatment which is 
considered as standard. The US patent for trastuzumab is set to expire in 
June 2019; it expired in July 2014 in Europe. The success of trastuzumab, 
in combination with its expired patent, has prompted the investment 
into competing biosimilars [33-36].
Although 19 biosimilars for trastuzumab are currently being 
investigated, MYL-1401O has shown the most success toward the 
patients with HER2-positive metastatic breast cancer [37,38]. As 
progression-free survival or overall survival may be insufficient to 
demonstrate biosimilarity between reference products and their 
biosimilars, bodies such as the EMA have recommended using an 
activity-measuring clinical endpoint such as partial complete response 
or oxygen reduction reaction (ORR) as the primary endpoint [39]. The 
primary outcome measure of this study was a comparison of the best 
ORR at week 24 between the combination of biosimilar trastuzumab 
(MYL-1401O) with taxane and reference trastuzumab with taxane. 
The study showed that patients receiving reference trastuzumab plus 
a taxane had an ORR of 64.0% at 24 weeks and patients receiving 
biosimilar trastuzumab plus a taxane had an ORR of 69.6%, a rate 
within pre-defined equivalence boundaries. Progression-free survival 
at 48 weeks was 44.7% and 44.3% for reference and biosimilar 
trastuzumab, respectively; overall survival was 85.1% and 89.1%, 
respectively; adverse events affected 94.7% and 98.6% of patients, 
respectively [40,41]. PF-05280014, another biosimilar of trastuzumab, 
was reported as having demonstrated equivalence in its primary 
endpoint in November of the past year; data from this study have not 
yet been presented [42]. Finally, biosimilar trastuzumab has been 
investigated only as a single agent, while trastuzumab plus pertuzumab 
is considered the standard of care. The development and testing of 
biosimilar drugs may continue to change the ways doctors to treat their 
patients. Increased understanding of the approval and testing process, 
as well as potential benefits and risks of the use of biosimilars, are 
essential for practicing oncologists. Biologic pharmaceutical options 
remain costly, and incorporation of biosimilars may lead to health-care 
savings of 30% or more, with market entry costs, pricing reactions, and 
many other factors establishing the ultimate level of cost reduction that 
may be seen [43].
CONCLUSION
Biologics or biopharmaceuticals or biotechnologically produced 
drugs are key growth enhancers in the pharmaceutical market [44]. 
Development of biosimilars provides the opportunity for drug 
manufactures to employ a comparator official outside the European 
Economy Area throughout the clinical study of biosimilars products. 
For the last three decades, the biosimilars are products which are 
growing rapidly in the market and mainly intended in the treatment 
of various incurable diseases. Biosimilar products are obtained from 
the living cells with high molecular weight and complex than chemical 
drugs. The EMA WHO and US FDA guidelines are some of the reference 
standard for many countries. 16 countries adopted these guidelines 
and 3 countries filled the drafts as the basis of their own regulations.
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